



Title of Invention

PI : Prof. Pan-Chyr Yang

Department of Medicine, National Taiwan U.

Experience: <http://www.ntu.edu.tw/administration/president.html>



Market Needs: Cancer remains an unsolved issue in modern medicine. Causes of cancer initiation is diverse and cancer cells evolve during disease progression and under drug selection pressure. Although the advances of chemotherapy, targeted therapy and immunotherapy have revolutionized cancer treatment to some extent, development of new therapeutics is still in high demand.

Our Technology: This includes a peptide that targets membrane receptor proteins, which are frequently overexpressed in cancers.

Strength: The peptide inhibits receptor activation and downstream signaling in a way not identical to current available drugs. Therefore, the peptide can overcome common drug-resistant mutations.

Competing Products: Small molecule drugs and monoclonal antibodies.

Intellectual Properties: No similar patent found.

Contact (do not need to fill out):

Center for Industry-Academia Cooperation, NTU
Tel: 02-3366-9945, E-mail: ntuciac@ntu.edu.tw

This information herein is intended for potential license of NTU technology only. Other usage of all or portion of this information in whatever form or means is strictly prohibited. Kindly contact us and we will help to achieve your goal the best we can.